FDA Fast Tracks Approval of Voxelotor to Treat Underlying Cause of Sickle Cell Disease | CheckRare.com
The U.S. Food and Drug Administration (FDA) has approved Oxbryta (voxelotor) to treat persons, 12 years and older, with sickle cell disease.
The U.S. Food and Drug Administration (FDA) has approved Oxbryta (voxelotor) to treat persons, 12 years and older, with sickle cell disease.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Judith Luker discusses the sudden unexpected death in epilepsy communication gap and the importance of physician-patient conversations.
Dr. Smith-Whitley, pediatric hematologist at the Children’s Hospital of Philadelphia, discusses the advances in sickle cell disease.
Dr. Varshavsky-Yanovsky discusses the safety of elranatamab in Black or African-American patients with multiple myeloma.
Approval allows Onivyde (plus oxaliplatin, fluorouracil, and leucovorin) as first-line therapy.
Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses the importance of rare disease registries.
We have noticed an unusual activity from your IP 199.16.157.182 and blocked access to this
Robin Kate Kelley, professor of clinical medicine, University of California, San Francisco, dissects biliary tract cancer.
We have noticed an unusual activity from your IP 199.16.157.183 and blocked access to this
Priya Kishnani, MD, Professor of Pediatrics at Duke University Medical Center, discusses intrauterine treatment for lysosomal diseases.